ArticleJournal of human genetics2026
A comprehensive assessment of pharmacogenomic annotation tools for next-generation sequencing data: an emphasis on cyp2d6 and vietnamese genomic data.
Article in Journal of human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Next-generation sequencing (NGS) offers a fast, cost-effective, and scalable solution for pharmacogenomic allele assignment but faces challenges in accurately identifying variants and haplotypes in regions with high sequence similarity. This study aimed to evaluate the performance of three NGS-compatible genotyping tools - PyPGx, Stargazer, and Aldy - for CYP2D6 annotation and investigated the CYP2D6 genetic distribution in 1008 whole-genome sequences from the 1000 Vietnamese Genome Project (VN1K) data. A benchmark dataset was constructed using 8556 diverse CYP2D6 alleles and 122 samples with complex structural variations. Tools were then assessed for haplotype, diplotype, and phenotype concordance across sequencing coverages of 8x, 30x, and 60x. Then, all three tools were subsequently applied to genotype CYP2D6 in the VN1K dataset. Overall, Aldy outperformed others, achieving haplotype and phenotype accuracies of 89.56% and 96.59%, respectively, even at low coverage (8x). In comparison, Stargazer and PyPGx achieved diplotype concordance rates of 51.33% and 47.77% under the same coverage level. According to the output of Aldy - the best performance tool in analysing the CYP2D6 genetic distribution in VN1K data, the results revealed a predominance of reduced-function alleles and a high prevalence of intermediate metabolizer phenotypes, underscoring the need for population-specific pharmacogenomic strategies and highlighting Aldy's potential in advancing precision medicine.
Indexed as
Identifiers
41162631What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.